Last reviewed · How we verify
NCT06798480: PURPLE
Prevalence of Problematic Use of Social Media
trial testing Self-administered survey in Social Networks in 1,000 participants. Not yet recruiting.
1 July 2025
Quick facts
| Lead sponsor | Hospices Civils de Lyon |
|---|---|
| Status | Not yet recruiting |
| Study type | OBSERVATIONAL |
| Enrollment | 1,000 |
| Start date | 1 April 2025 |
| Primary completion | 1 July 2025 |
| Estimated completion | 1 July 2025 |
| Sites | 1 location across France |
Drugs / interventions tested
- Self-administered survey
Conditions studied
- Social Networks — all drugs for Social Networks →
- Addiction — all drugs for Addiction →
Sponsor
Hospices Civils de Lyon — full company profile →
Who can join
13 and older, any sex, with Social Networks or Addiction. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
In 2023, French individuals spend an average of two hours per day on social media platforms (SM), primarily Facebook, TikTok, X, YouTube, Instagram, and Snapchat. While social media offers undeniable benefits, it also raises concerns about its impact on mental health and well-being. These impacts remain poorly understood, partly due to the diversity of social media uses and motivations, which do not have uniform effects on health. For instance, studies have shown that "active" use of social media (e.g., content creation) is associated with higher well-being, whereas "passive" use (e.g., content scrolling) is linked to lower well-being. This challenge in understanding the variety of social media uses and their consequences has direct clinical implications. Clinicians working in pediatrics, child psychiatry, and addiction medicine are increasingly confronted with patients struggling to manage their social media use. However, they lack clear diagnostic criteria to differentiate between normal and problematic use, as well as specific tools tailored to address potential disorders. Moreover, in France, there is no existing estimate of the proportion of the general population affected by problematic social media use. This study aims to establish the prevalence of problematic use of social media in France. The investigators hypothesize that the prevalence will be close to 10%, which is the prevalence that has been found in other European countries in previous studies.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT06798480
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Social Networks
Currently open trials in the same condition.
- NCT07393529 — A Pilot Randomized Controlled Trial of a Social Network Intervention · NA · recruiting
Other Hospices Civils de Lyon trials
Trials by the same sponsor.
- NCT07569536 — Efficacy of the Alpha 2 Agonist Dexmedetomidine for Sympathetic Deactivation in REfractory Septic Shock · Phase 3 · not yet recruiting
- NCT07529314 — Evaluating Interventional Radiology for Cancer Pain Management · NA · not yet recruiting
- NCT07273929 — Comparative Study of the Effectiveness of Three Access Routes for Implanting an Electronic Intracardiac Device · Phase 3 · not yet recruiting
- NCT07474532 — Attitudes and Beliefs Related to Benzodiazepine Deprescribing · not yet recruiting
- NCT07313007 — Assessment of Gut Microbiota-Derived Amino Acid Metabolite Production in Patients With MASLD · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06798480 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Hospices Civils de Lyon
- Last refreshed: 5 March 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06798480.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing